Bharat Immunologicals & Biologicals Corporation Limited reported unaudited earnings results for the second quarter and six months ended September 30, 2018. For the quarter, the company’s income from operations was INR 46.722 million against INR 53.051 million for the same period a year ago. Total revenue was INR 47.758 million against INR 55.753 million for the same period a year ago. Loss from continuing operations was INR 25.066 million against INR 23.893 million for the same period a year ago. Total comprehensive loss was INR 25.066 million against INR 23.893 million for the same period a year ago. Basic and diluted loss per share was INR 0.58 against INR 0.55 for the same period a year ago. Loss before finance cost and exceptional items was INR 37.011 million against INR 22.682 million a year ago. For the six months, the company’s income from operations was INR 47.589 million, total revenue was INR 52.020 million, loss from continuing operations was INR 37.489 million and total comprehensive loss was INR 33.330 million or INR 0.87 per basic and diluted share. Loss before finance cost and exceptional items was INR 49.434 million.